Drug intelligence / Profile preview

RTx-015

Development stage: Unknown
Lead developer: Ray Therapeutics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intravitreal

Overview

RTx-015 is an investigational optogenetic gene therapy developed by Ray Therapeutics for the treatment of inherited retinal degenerative diseases. It utilizes an adeno-associated virus (AAV.7m8) vector to deliver a gene encoding a light-sensitive opsin protein to retinal ganglion cells (RGCs) via intravitreal injection. The goal is to restore visual function in patients with advanced retinitis pigmentosa and potentially other blinding conditions by enabling surviving inner retinal neurons to respond to light after photoreceptor loss. The therapy is currently being evaluated in Phase 1 clinical trials for retinitis pigmentosa and choroideremia[2][3][6][9].

Targets

OPN4 (Melanopsin)

Beyond the preview

Go deeper on RTx-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RTx-015.

Explore the full profile